Jaguar Health, Inc. (NASDAQ:JAGX)

PRESS RELEASE

published on 11/19/2024 at 15:30, 1 year 7 months ago

Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe”
Jaguar Health's Napo Therapeutics awarded 'Best Pharmaceuticals Innovator of the Year - Europe' for expanding access to crofelemer in Europe for orphan and rare diseases. Partnering with Jaguar and Napo Pharmaceuticals for clinical studies

Crofelemer Jaguar Health Rare Diseases Orphan Diseases Napo Therapeutics
BRIEF

published on 11/13/2024 at 14:05, 1 year 7 months ago

Jaguar Health Reports Strong Q3 2024 Financial Performance

Financial Results Crofelemer Jaguar Health Q3 2024 Cancer Supportive Care
BRIEF

published on 11/13/2024 at 14:05, 1 year 7 months ago

Jaguar Health annonce de solides résultats financiers au troisième trimestre 2024

Résultats Financiers Crofelemer Santé Jaguar 3e Trimestre 2024 Soins De Soutien Aux Personnes Atteintes De Cancer
PRESS RELEASE

published on 11/13/2024 at 14:00, 1 year 7 months ago

Jaguar Health Reports Third Quarter 2024 Financial Results
Jaguar Health, Inc. reports a 14% revenue increase in Q3 2024, introduces Gelclair commercial launch. Initiates Phase 2 trials and IIT studies. Hosts investor webcast on November 13

Revenue Increase Jaguar Health Q3 2024 Phase 2 Trials Gelclair
BRIEF

published on 11/11/2024 at 14:35, 1 year 7 months ago

Jaguar Health to Discuss Q3 2024 Financials in Upcoming Investor Webcast

Napo Pharmaceuticals Crofelemer Investor Webcast Jaguar Health Q3 Financials
BRIEF

published on 11/11/2024 at 14:35, 1 year 7 months ago

Jaguar Health discutera des résultats financiers du troisième trimestre 2024 lors d'un prochain webcast destiné aux investisseurs

Crofelemer Santé Jaguar Napo Pharmaceutique Résultats Financiers Du Troisième Trimestre Webcast Pour Les Investisseurs
PRESS RELEASE

published on 11/11/2024 at 14:30, 1 year 7 months ago

Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates
Jaguar Health, Inc. (NASDAQ:JAGX) to conduct investor webcast on November 13, 2024 at 8:30 a.m. Eastern to review Q3 2024 financials and provide corporate updates

Investor Webcast Jaguar Health Corporate Updates Q3 Financials NASDAQ:JAGX
BRIEF

published on 11/06/2024 at 16:05, 1 year 7 months ago

FDA Renews Approval for Canalevia-CA1, Jaguar Health's Canine Diarrhea Drug

FDA Approval Veterinary Medicine Jaguar Health Canalevia-CA1 Chemotherapy-induced Diarrhea
BRIEF

published on 11/06/2024 at 16:05, 1 year 7 months ago

La FDA renouvelle l'approbation de Canalevia-CA1, le médicament contre la diarrhée canine de Jaguar Health

Canalevia-CA1 Approbation De La FDA Santé Jaguar Médecine Vétérinaire Diarrhée Induite Par La Chimiothérapie
PRESS RELEASE

published on 11/06/2024 at 16:00, 1 year 7 months ago

FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs
Jaguar Health, Inc. announces FDA conditional approval renewal of Canalevia-CA1 for chemotherapy-induced diarrhea in dogs. Canalevia-CA1, a crofelemer tablet, is available from major U.S. veterinary distributors

Crofelemer FDA Approval Jaguar Health Canalevia-CA1 Chemotherapy-induced Diarrhea

Published on 06/27/2026 at 01:40, 4 hours 52 minutes ago

Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Published on 06/27/2026 at 00:00, 6 hours 32 minutes ago

Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 7 hours 32 minutes ago

Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 7 hours 42 minutes ago

Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/26/2026 at 22:15, 8 hours 17 minutes ago

Revive Therapeutics Announces Proposed Private Placement

View all ACCESSWIRE

Published on 06/27/2026 at 00:05, 6 hours 27 minutes ago

EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Published on 06/27/2026 at 00:04, 6 hours 28 minutes ago

Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 6 hours 56 minutes ago

Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 6 hours 56 minutes ago

EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Published on 06/26/2026 at 23:27, 7 hours 4 minutes ago

EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE

View all EQS

Published on 06/26/2026 at 17:45, 12 hours 47 minutes ago

Combined General Meeting, June 25, 2026
Published on 06/26/2026 at 17:45, 12 hours 47 minutes ago

Assemblée générale mixte du 25 juin 2026
Published on 06/26/2026 at 17:45, 12 hours 47 minutes ago

Descriptif du programme de rachat d'actions
Published on 06/26/2026 at 14:44, 15 hours 47 minutes ago

Safran information
Published on 06/26/2026 at 14:44, 15 hours 47 minutes ago

Information Safran

View all LES ECHOS COMFI WIRE

News